Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
Repligen to Report First Quarter 2026 Financial Results
07:30am, Wednesday, 22'nd Apr 2026
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET
Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
07:30am, Friday, 17'th Apr 2026
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its
Massachusetts Financial Services Co. MA Makes New $199.18 Million Investment in Repligen Corporation $RGEN
05:28am, Monday, 13'th Apr 2026
Massachusetts Financial Services Co. MA acquired a new position in Repligen Corporation (NASDAQ: RGEN) in the fourth quarter, according to the company in its most recent filing with the Securities and
Azzad Asset Management Inc. ADV Has $543,000 Position in Repligen Corporation $RGEN
03:40am, Thursday, 09'th Apr 2026
Azzad Asset Management Inc. ADV cut its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 59.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Ex
Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?
12:32pm, Thursday, 26'th Mar 2026
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Corporation $RGEN Stock Position Raised by Congress Asset Management Co.
01:39pm, Tuesday, 24'th Mar 2026
Congress Asset Management Co. grew its position in shares of Repligen Corporation (NASDAQ: RGEN) by 241.4% in the undefined quarter, according to the company in its most recent filing with the Securit
Repligen Conference: CEO touts differentiated bioprocessing portfolio; CFO targets 30% EBITDA margin
02:03am, Monday, 23'rd Mar 2026
Repligen (NASDAQ: RGEN) executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution during a recent discussion with Life Science Analyst Paul Knight. Chief Execut
Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
04:42pm, Wednesday, 18'th Mar 2026
Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Cinctive Capital Management LP Takes Position in Repligen Corporation $RGEN
04:31am, Monday, 16'th Mar 2026
Cinctive Capital Management LP bought a new stake in shares of Repligen Corporation (NASDAQ: RGEN) during the undefined quarter, according to its most recent filing with the SEC. The firm bought 25,42
Repligen Corporation (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages
02:51am, Friday, 13'th Mar 2026
Shares of Repligen Corporation (NASDAQ: RGEN - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are presently covering the firm, Marketbeat reports. O
Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
02:20pm, Tuesday, 10'th Mar 2026
Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
10:11am, Wednesday, 25'th Feb 2026
RGEN tops Q4 EPS estimates as revenues jump 18% Y/Y, with solid organic growth and stronger margins heading into 2026.
Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript
02:28pm, Tuesday, 24'th Feb 2026
Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
10:40am, Tuesday, 24'th Feb 2026
Repligen (RGEN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.44 per share a year ago.
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
07:30am, Tuesday, 24'th Feb 2026
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f
